Structure via PubChem · Public domain (PubChem)
methoxphenidine
Sign in to saveMethoxphenidine (methoxydiphenidine, 2-MeO-Diphenidine, MXP) is a dissociative of the diarylethylamine class that has been sold online as a designer drug. Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury. Shortly after the 2013 UK ban on arylcyclohexylamines methoxphenidine and the related compound diphenidine became available on the gray market, where it has been encountered as a powder and in tablet form. Though diphenidine possesses higher affinity for the NMDA receptor, anecdotal reports suggest methoxphenidine has greater oral po
In the Vinony graph
Vinony's link graph records 1,556 inbound references to methoxphenidine, and connects out to 2C-G, D-methamphetamine and benzylamine.
It sits within the topics 1,2-Diarylethylamines, 1-Piperidinyl compounds and 2-Methoxyphenyl compounds.
Vinony links it to 4 Wikipedia language editions.
Chemical data
- Formula
- C20H25NO
- Molecular weight
- 295.4 g/mol
- IUPAC name
- 1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine
- SMILES
- COC1=CC=CC=C1C(CC2=CC=CC=C2)N3CCCCC3
- InChIKey
- QXXCUXIRBHSITD-UHFFFAOYSA-N
- XLogP
- 4.6
- Polar surface area
- 12.5 Ų
- H-bond donors
- 0
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 295.194
Show 3 more facts
- chemical formula
- C₂₀H₂₅NO
- canonical SMILES
- COC1=CC=CC=C1C(CC2=CC=CC=C2)N3CCCCC3
- Commons category
- Methoxphenidine
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
4 sectionsContents
- Side effects
- Legal status
- See also
- References
Methoxphenidine (methoxydiphenidine, 2-MeO-Diphenidine, MXP) is a dissociative of the diarylethylamine class that has been sold online as a designer drug. Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury. Shortly after the 2013 UK ban on arylcyclohexylamines methoxphenidine and the related compound diphenidine became available on the gray market, where it has been encountered as a powder and in tablet form. Though diphenidine possesses higher affinity for the NMDA receptor, anecdotal reports suggest methoxphenidine has greater oral potency. Of the three isomeric anisyl-substituents methoxphenidine has affinity for the NMDA receptor that is higher than 4-MeO-diphenidine but lower than 3-MeO-diphenidine, a structure–activity relationship shared by the arylcyclohexylamines.
== Side effects ==
Excerpted from Wikipedia’s “methoxphenidine” article, available under the CC BY-SA 4.0 licence.